OBJECTIVES: At the end of 2006, there was an important reform in the Hungarian pharmaceutical market, including serious changes in the health insurance reimbursement of medicines. The aim of our study is to analyze the changes in the Hungarian health insurance pharmaceutical budget between 2007-2013. METHODS: Data were derived from the nationwide administrative dataset of the National Health Insurance Fund Administration (OEP), the only health care financing agency in Hungary. We analyzed the changes of the health insurance pharmaceutical budget between 2007-2013. Results are given in Hungarian Forint (HUF) and US dollars (USD). The annual average currency exchange rates were applied according to the data of the Central Bank of Hungary. RESULTS: The Hungarian pharmaceutical budget was 323.6 (2007), 325.7 (2008), 343.2 (2009), 357.2 (2010), 376.9 (2011), 315.1 (2012) and 280.0 (2013) billion HUF. The average annual exchange rate between Hungarian Forint and US dollar was 183.83 (2007), 171.80 (2008), 202.26 (2009), 208.15 (2010), 200.94 (2011), 225.37 (2012) and 223.70 (2013), which means that Hungarian Forint significantly weakened compared to USD. After the changes in currency exchange rate, the Hungarian pharmaceutical budget measured by US dollars was 1.76 (2007), 1.90 (2008), 1.70 (2009), 1.72 (2010), 1.88 (2011), 1.40 (2012) and 1.25 (2013) billion USD. The decrease of pharma reimbursement budget from 2011 to 2013 was more significant in USD dollar (33.3 %) than in Hungarian Forint (25.7 %) due to the weakened Hungarian currency. CONCLUSIONS: Due to the reform of the whole Hungarian pharmaceutical market, the Hungarian health insurance pharmaceutical budget significantly changed between 2007-2013. This change was more remarkable in USD as the Hungarian currency weakened compared USD during the world economic crisis.